Bio-Rad Laboratories (BIO) Receivables (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Receivables data on file, last reported at $439.5 million in Q1 2026.

• Quarterly Receivables changed 0.25% year-over-year to $439.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $439.5 million (changed 0.25% YoY) and the FY2025 annual result came in at $472.5 million, up 1.48% from the prior year.
• Receivables declined to $439.5 million in Q1 2026 per BIO's latest filing, from $472.5 million in the prior quarter.
• Across five years, Receivables topped out at $513.1 million in Q1 2023 and bottomed at $438.4 million in Q1 2025.
• The 5-year median for Receivables is $470.7 million (2022), against an average of $471.4 million.
• The widest annual swing landed in 2022, when Receivables increased 18.91%; it then fell 10.42% in 2024.
• Tracing BIO's Receivables over 5 years: stood at $506.2 million in 2022, then fell by 1.06% to $500.9 million in 2023, then decreased by 7.05% to $465.6 million in 2024, then increased by 1.48% to $472.5 million in 2025, then retreated by 6.98% to $439.5 million in 2026.
• Per Business Quant, the three latest BIO Receivables figures stand at $439.5 million (Q1 2026), $472.5 million (Q4 2025), and $474.2 million (Q3 2025).

Peer Comparison